OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Sinovac Biotech, BSX, LLY, EWTX, ELVN, and represent 31.51% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: CAI (+$81M), UNH (+$58M), ROIV (+$31M), VRTX (+$22M), CTMX (+$19M), EW (+$14M), RAPT (+$13M), TRVI (+$12M), JANX (+$10M), MLYS (+$10M).
- Started 16 new stock positions in JBIO, CPRX, ROIV, INMB, CAI, AZN, MLYS, URGN, MURA, RAPT. ZLAB, ALMS, ASND, LYEL, CTMX, Iteos Therapeutics.
- Reduced shares in these 10 stocks: PFE (-$110M), IONS (-$77M), NBIX (-$62M), SWTX (-$50M), XTNT (-$34M), TMO (-$34M), ITGR (-$28M), GILD (-$22M), CMPX (-$19M), TARS (-$19M).
- Sold out of its positions in Acelyrin, IVVD, AMGN, BCAX, PHGE, CRDF, CBLL, FATE, GILD, TIL. IONS, NXTC, NKTX, PFE, Rapt Therapeutics, XBI, SRRK, SWTX, TNGX, VSTM, VERA, XTNT, X4 Pharmaceuticals, KMTS.
- Orbimed Advisors was a net seller of stock by $-271M.
- Orbimed Advisors has $4.0B in assets under management (AUM), dropping by -4.54%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 99 positions in its portfolio as reported in the June 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Sinovac Biotech SHS | 8.3 | $334M | 2.7M | 122.85 |
|
|
| Boston Scientific Corporation (BSX) | 7.5 | $302M | 2.8M | 107.41 |
|
|
| Eli Lilly & Co. (LLY) | 6.6 | $263M | 338k | 779.53 |
|
|
| Edgewise Therapeutics (EWTX) | 5.1 | $203M | +3% | 16M | 13.11 |
|
| Enliven Therapeutics (ELVN) | 4.0 | $160M | 8.0M | 20.06 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.9 | $158M | 291k | 543.41 |
|
|
| Silverback Therapeutics (SPRY) | 3.6 | $145M | 8.3M | 17.45 |
|
|
| Stryker Corporation (SYK) | 3.5 | $142M | 359k | 395.63 |
|
|
| Edwards Lifesciences (EW) | 3.3 | $134M | +11% | 1.7M | 78.21 |
|
| UnitedHealth (UNH) | 3.0 | $121M | +91% | 386k | 311.97 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.9 | $115M | 208k | 551.22 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 2.8 | $112M | 342k | 326.09 |
|
|
| Natera (NTRA) | 2.5 | $100M | +8% | 593k | 168.94 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.3 | $94M | +31% | 210k | 445.20 |
|
| Tenet Healthcare Corp Com New (THC) | 2.0 | $82M | 465k | 176.00 |
|
|
| Caris Life Sciences (CAI) | 2.0 | $81M | NEW | 3.0M | 26.72 |
|
| Disc Medicine (IRON) | 1.9 | $75M | 1.4M | 52.96 |
|
|
| Arrivent Biopharma (AVBP) | 1.6 | $66M | 3.0M | 21.77 |
|
|
| Sionna Therapeutics (SION) | 1.6 | $64M | 3.7M | 17.35 |
|
|
| Upstream Bio (UPB) | 1.6 | $63M | 5.7M | 10.98 |
|
|
| Neurocrine Biosciences (NBIX) | 1.4 | $55M | -53% | 439k | 125.69 |
|
| Integer Hldgs (ITGR) | 1.3 | $53M | -34% | 433k | 122.97 |
|
| Cg Oncology (CGON) | 1.3 | $53M | -17% | 2.0M | 26.00 |
|
| Avidity Biosciences Ord (RNA) | 1.3 | $52M | 1.8M | 28.40 |
|
|
| Si-bone (SIBN) | 1.2 | $49M | -25% | 2.6M | 18.82 |
|
| Mbx Biosciences (MBX) | 1.1 | $46M | 4.0M | 11.41 |
|
|
| Axsome Therapeutics (AXSM) | 1.1 | $45M | +10% | 428k | 104.39 |
|
| Compass Therapeutics (CMPX) | 1.0 | $40M | -31% | 15M | 2.60 |
|
| Cytokinetics Com New (CYTK) | 0.9 | $36M | -28% | 1.1M | 33.04 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $33M | +15% | 1.1M | 28.76 |
|
| EXACT Sciences Corporation (EXAS) | 0.8 | $32M | -10% | 607k | 53.14 |
|
| Third Harmonic Bio (THRD) | 0.8 | $31M | 5.8M | 5.43 |
|
|
| Roivant Sciences SHS (ROIV) | 0.8 | $31M | NEW | 2.8M | 11.27 |
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $30M | 948k | 31.30 |
|
|
| Neuropace (NPCE) | 0.7 | $29M | -23% | 2.6M | 11.14 |
|
| Corvus Pharmaceuticals (CRVS) | 0.7 | $29M | +3% | 7.2M | 4.00 |
|
| Terns Pharmaceuticals (TERN) | 0.7 | $28M | 7.6M | 3.73 |
|
|
| Janux Therapeutics (JANX) | 0.7 | $28M | +59% | 1.2M | 23.10 |
|
| Apellis Pharmaceuticals Call Option (APLS) | 0.7 | $27M | +6% | 1.5M | 17.31 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.6 | $25M | +49% | 1.2M | 20.74 |
|
| Scpharmaceuticals (SCPH) | 0.6 | $23M | 6.1M | 3.81 |
|
|
| Cytomx Therapeutics (CTMX) | 0.5 | $19M | NEW | 8.5M | 2.27 |
|
| Thermo Fisher Scientific (TMO) | 0.5 | $19M | -63% | 47k | 405.46 |
|
| Agios Pharmaceuticals (AGIO) | 0.5 | $19M | +71% | 558k | 33.26 |
|
| Trevi Therapeutics (TRVI) | 0.5 | $18M | +195% | 3.3M | 5.47 |
|
| Ikena Oncology Nonvoting | 0.4 | $16M | 12M | 1.34 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 0.4 | $16M | 5.9M | 2.68 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.4 | $16M | -34% | 249k | 63.19 |
|
| Forte Biosciences Com New (FBRX) | 0.4 | $16M | +101% | 1.2M | 12.93 |
|
| Cullinan Oncology (CGEM) | 0.4 | $15M | 1.9M | 7.53 |
|
|
| Keros Therapeutics (KROS) | 0.3 | $14M | 1.0M | 13.35 |
|
|
| Rapt Therapeutics Com New (RAPT) | 0.3 | $13M | NEW | 1.6M | 8.00 |
|
| Amicus Therapeutics (FOLD) | 0.3 | $13M | 2.3M | 5.73 |
|
|
| Vir Biotechnology (VIR) | 0.3 | $12M | +5% | 2.4M | 5.04 |
|
| Abcellera Biologics (ABCL) | 0.3 | $12M | -20% | 3.3M | 3.43 |
|
| Akero Therapeutics (AKRO) | 0.3 | $11M | +17% | 211k | 53.36 |
|
| Mineralys Therapeutics (MLYS) | 0.3 | $10M | NEW | 760k | 13.53 |
|
| Dyne Therapeutics (DYN) | 0.2 | $9.8M | 1.0M | 9.52 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 0.2 | $9.8M | 6.8M | 1.43 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.2 | $9.1M | +28% | 899k | 10.15 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 0.2 | $9.0M | NEW | 417k | 21.70 |
|
| Prelude Therapeutics (PRLD) | 0.2 | $8.8M | 11M | 0.81 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.2 | $8.1M | 1.2M | 6.90 |
|
|
| Zai Lab Adr (ZLAB) | 0.2 | $8.1M | NEW | 231k | 34.97 |
|
| Tarsus Pharmaceuticals (TARS) | 0.2 | $8.0M | -69% | 198k | 40.51 |
|
| Aadi Bioscience (WHWK) | 0.2 | $7.8M | 4.2M | 1.87 |
|
|
| Tyra Biosciences (TYRA) | 0.2 | $7.7M | -54% | 805k | 9.57 |
|
| Astrazeneca Sponsored Adr Call Option (AZN) | 0.2 | $7.0M | NEW | 100k | 69.88 |
|
| Adicet Bio (ACET) | 0.2 | $7.0M | 11M | 0.61 |
|
|
| Iteos Therapeutics | 0.2 | $7.0M | NEW | 700k | 9.97 |
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $6.9M | 6.5M | 1.06 |
|
|
| Urogen Pharma (URGN) | 0.2 | $6.6M | NEW | 478k | 13.70 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.1 | $5.9M | NEW | 34k | 172.60 |
|
| Alumis (ALMS) | 0.1 | $5.8M | NEW | 1.9M | 3.00 |
|
| Jade Biosciences Com New (JBIO) | 0.1 | $5.3M | NEW | 531k | 9.99 |
|
| Inspiremd (NSPR) | 0.1 | $4.8M | 2.1M | 2.27 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $4.8M | 967k | 4.99 |
|
|
| Ikena Oncology (IKNA) | 0.1 | $4.7M | 3.5M | 1.34 |
|
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $4.6M | 3.3M | 1.39 |
|
|
| Immatics SHS (IMTX) | 0.1 | $3.9M | -76% | 720k | 5.38 |
|
| Bioage Labs (BIOA) | 0.1 | $3.8M | 922k | 4.13 |
|
|
| Q32 Bio (QTTB) | 0.1 | $3.4M | 2.3M | 1.49 |
|
|
| Engene Holdings (ENGN) | 0.1 | $2.5M | -23% | 678k | 3.64 |
|
| Passage Bio | 0.1 | $2.4M | -13% | 6.1M | 0.40 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $2.0M | -10% | 313k | 6.41 |
|
| Mural Oncology Pub Ord Shs (MURA) | 0.0 | $1.5M | NEW | 589k | 2.47 |
|
| Insmed Com Par $.01 (INSM) | 0.0 | $1.4M | -53% | 14k | 100.64 |
|
| Krystal Biotech (KRYS) | 0.0 | $1.3M | -60% | 9.2k | 137.46 |
|
| Turnstone Biologics Corp (TSBX) | 0.0 | $1.1M | 3.1M | 0.36 |
|
|
| Chemomab Therapeutics Sponsored Ads | 0.0 | $1.1M | -45% | 941k | 1.16 |
|
| Traws Pharma Com New (TRAW) | 0.0 | $896k | 606k | 1.48 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.0 | $883k | 193k | 4.58 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.0 | $550k | 250k | 2.20 |
|
|
| Dih Hldg Us Cl A (DHAI) | 0.0 | $469k | 1.9M | 0.24 |
|
|
| Lyell Immunopharma Com New (LYEL) | 0.0 | $457k | NEW | 52k | 8.84 |
|
| Korro Bio (KRRO) | 0.0 | $405k | 32k | 12.49 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $376k | 80k | 4.67 |
|
|
| Inmune Bio Ord Put Option (INMB) | 0.0 | $116k | NEW | 50k | 2.31 |
|
| Lakeshore Biopharma Ord Shs New (LSBCF) | 0.0 | $56k | -60% | 55k | 1.02 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2025 Q2 filed Aug. 14, 2025
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021